Abstract

Isocitrate dehydrogenase 1 (IDH1)-wildtype glioblastoma (GBM) has found to be accompanied with increased expression of branched-chain amino acid trasaminase1 (BCAT1), which is associated with tumor growth and disease progression. In this retrospective study, quantitative RT-PCR, immunohistochemistry, and western blot were performed with GBM patient tissues to evaluate the BCAT1 level. Quantitative MR imaging parameters were evaluated from DSC perfusion imaging, DWI, contrast-enhanced T1WI and FLAIR imaging using a 3T MR scanner. The level of BCAT1 was significantly higher in IDH1-wildtype patients than in IDH1-mutant patients obtained in immunohistochemistry and western blot. The BCAT1 level was significantly correlated with the mean and 95th percentile-normalized CBV as well as the mean ADC based on FLAIR images. In addition, the 95th percentile-normalized CBV from CE T1WI also had a significant correlation with the BCAT1 level. Moreover, the median PFS in patients with BCAT1 expression <100 was longer than in those with BCAT1 expression ≥100. Taken together, we found that a high BCAT1 level is correlated with high CBV and a low ADC value as well as the poor prognosis of BCAT1 expression is related to the aggressive nature of GBM.

Highlights

  • Several previous studies evaluated the expression and role of branched-chain amino acid trasaminase[1] (BCAT1) in Isocitrate dehydrogenase 1 (IDH1)-wildtype glioma[5,6,7,8,9]

  • The 95% normalized cerebral blood volume (nCBV) value from the enhancing area based on CE T1-weighted imaging (T1WI) had a significant correlation with the branched-chain amino acid trasaminase1 (BCAT1) expression level (r = 0.2689, P = 0.0255)

  • We assessed the quantitative MR imaging features and prognosis related to the BCAT1 expression level in GBM patients

Read more

Summary

Introduction

Several previous studies evaluated the expression and role of branched-chain amino acid trasaminase[1] (BCAT1) in IDH1-wildtype glioma[5,6,7,8,9]. Noninvasive assessment of BCAT1 activity could help with the diagnosis and monitoring of IDH1-wildtype GBM In this regard, a previous study demonstrated that bevacizumab resistance increased with the expression of BCAT1 in IDH1-wildtype rat GBM, which was assessed by dynamic contrast susceptibility (DSC) perfusion MRI. Parameter No of patients Mean age (y) Sex Male Female Mean radiation dose (Gy) IDH mutation status IDH1-wildtype IDH1-mutant IDH2-wildtype IDH2-mutant MGMT promoter methylation status Methylated Unmethylated of anti-angiogenic treatment in IDH1-wildtype rat GBM9. These results raise the question of which MR imaging parameters can be used as representative imaging biomarkers for predicting BCAT1 expression in IDH1-wildtype GBM patients. In this study, we sought to assess the MR imaging features and prognosis related to the expression level of BCAT1 in IDH1-wildtype GBM

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call